Showing results (51-60 of 183) with videos related to
Sort By:
Pageof 19
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 19, 2018
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40)Arkaitz Imaz, Jordi Niubó, Mackenzie L Cottrell, et al.AIDS Research and Human Retroviruses|June 9, 2009
How much fat loss is needed for lipoatrophy to become clinically evident?Daniel Podzamczer, Elena Ferrer, Esteban Martínez, et al.HIV Medicine|March 25, 2025
Biomarkers of inflammation and coagulation predict non-AIDS-defining events in a prospective cohort of virologically suppressed people living with HIVMaria Saumoy, Analuz Fernandez, Juan Tiraboschi, et al.Journal of the International AIDS Society|November 14, 2014
Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTCJosé Ramón Santos, María Saumoy, Adrian Curran, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|December 2, 2023
Development and validation of equilibrium dialysis UHPLC-MS/MS measurement procedures for total and unbound concentrations of bictegravir, dolutegravir, darunavir and doravirine in human plasma. Application to patients with HIVRaúl Rigo-Bonnin, Laura García-Tejada, Virgínia Mas-Bosch, et al.HIV Clinical Trials|February 6, 2010
Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppressionJosé R Santos, Josep M Llibre, Elena Ferrer, et al.AIDS Research and Human Retroviruses|June 3, 2016
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical PracticeMaria Saumoy, Josep M Llibre, Alberto Terrón, et al.The Journal of Infectious Diseases|December 1, 2019
Total and Unbound Bictegravir Concentrations and Viral Suppression in Cerebrospinal Fluid of Human Immunodeficiency Virus-Infected Patients (Spanish HIV/AIDS Research Network, PreEC/RIS 56)Juan Tiraboschi, Arkaitz Imaz, Saye Khoo, et al.AIDS (London, England)|July 29, 2004
Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcomaLuz Martin-Carbonero, Ana Barrios, Pere Saballs, et al.Antiviral Therapy|January 25, 2014
Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/mlArkaitz Imaz, Josep M Llibre, Jordi Navarro, et al.Pageof 19